Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
World game at war: why some European nations have threatened a World Cup boycott 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
 April 26, 2018 in New York City - EconoTimes)
Geneva, Switzerland and Boston, MA - April 16, 2018- ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that the company will host a key opinion leader (KOL) meeting focused on in vitro fertilization (IVF) Thursday, April 26 from 12:00 to 2:00 p.m. ET in New York City.
The meeting will feature presentations from David Seifer, M.D., Professor of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, and Annette Lee M.D., Medical Director, Toll Center for Reproductive Sciences, Abington Reproductive Medicine. Additionally, members of the ObsEva management team will provide an overview of the company's oral oxytocin receptor antagonist nolasiban, including recently released positive top line results from the Phase 3 IMPLANT2 clinical trial.
A live webcast of the meeting will be accessible under the "Investors" section of ObsEva's website www.obseva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
202-955-6222 x2526
CEO Office Contact:
Shauna Dillon
[email protected]
+41 22 552 1550
Investor Contact:
Mario Corso
Senior Director, Investor Relations
[email protected]
857-972-9347 office
781-366-5726 mobile
Attachment
